Advanced search
Publication Cover
Expert Review of Medical Devices Volume 9, 2012 - Issue 3
Submit an article Journal homepage
406
Views
12
CrossRef citations to date
0
Altmetric
Device Profile

FlexTouch® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals

Timothy Bailey AMCR Institute Inc., 700 West El Norte Parkway Suite 201, Escondido, CA 92026, USA. [email protected]; AMCR Institute Inc., 700 West El Norte Parkway Suite 201, Escondido, CA 92026, USA. [email protected]
&
Carlos Campos AMCR Institute Inc., 700 West El Norte Parkway Suite 201, Escondido, CA 92026, USA. [email protected]; The Institute for Public Health and Education Research, 189 East Austin Street, Suite 102, New Braunfels, TX 78130, USA
Pages 209-217 | Published online: 09 Jan 2014

References

  • IMS Health. Estimated number of patients using FlexPen®, based on worldwide sales in number of packs sold, IMS world wide data Q4’07 and Daily Defined Dosage (DDD) for insulin as issued by WHO (2007).
  • Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad. Med. 106(5), 57–58, 61–64, 68 (1999).
  • Lee LJ, Li Q, Reynolds MW, Engelman W. Trend analyses of insulin delivery systems in the United States. J. Diabetes Sci. Technol. 5(5), 1116–1123 (2011).
  • Albano S; The ORBITER Study Group. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. Acta Biomed. 75(1), 34–39 (2004).
  • Lombardo F, Salzano G, Messina MF, De Luca F. Compliance and administration methods in management of Type 1 diabetes. Acta Biomed. 76(Suppl. 3), 66–69 (2005).
  • Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin. Ther. 26(9), 1498–1505 (2004).
  • Thurman JE. Insulin pen injection devices for management of patients with Type 2 diabetes: considerations based on an endocrinologist’s practical experience in the United States. Endocr. Pract. 13(6), 672–678 (2007).
  • Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 27(10), 2495–2497 (2004).
  • Stockl K, Ory C, Vanderplas A et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr. Med. Res. Opin. 23(1), 133–146 (2007).
  • Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch. Dis. Child. 79(1), 59–62 (1998).
  • Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin. Pediatr. (Phila.) 43(1), 69–74 (2004).
  • Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with Type 1 diabetes. Diabetes Care 22(1), 137–140 (1999).
  • Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296–1310 (2001).
  • Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with Type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin. Ther. 28(10), 1712–1725 (2006).
  • Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin. Ther. 20(3), 486–496 (1998).
  • Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv. Ther. 27(2), 94–104 (2010).
  • Arslanoglu I, Saka N, Bundak R, Gunoz H, Darendeliler F. A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia? J. Pediatr. Endocrinol. Metab. 13(3), 313–318 (2000).
  • Berger AS, Saurbrey N, Kuhl C, Villumsen J. Clinical experience with a new device that will simplify insulin injections. Diabetes Care 8(1), 73–76 (1985).
  • Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res. Clin. Pract. 28(3), 173–177 (1995).
  • Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle phobia in young patients with IDDM. Pract. Diabetes Int.14(4), 95–99 (1997).
  • Kadiri A, Chraibi A, Marouan F et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res. Clin. Pract. 41(1), 15–23 (1998).
  • Kolendorf K, Beck-Nielsen H, Oxenboll B. Clinical experience with NovoPen II and insulin Protaphane HM Penfill. Postgrad. Med. J. 64(Suppl. 3), 14–16; discussion 21 (1988).
  • Asakura T. Comparison of clinically relevant technical attributes of five insulin injection pens. J. Diabetes Sci. Technol. 5(5), 1203–1209 (2011).
  • Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely used prefilled insulin pen. Expert Opin. Drug Deliv. 8(10), 1271–1276 (2011).
  • Hemmingsen H, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol. Ther. 13(12), 1207–1211 (2011).
  • Asakura T, Seino H, Kageyama M, Yohkoh N. Evaluation of injection force of three insulin delivery pens. Expert Opin. Pharmacother. 10(9), 1389–1393 (2009).
  • Rissler J, Jorgensen C, Rye Hansen M, Hansen N-A. Evaluation of injection force dynamics of a modified prefilled insulin pen. Expert Opin. Pharmacother. 9(13), 2217–2222 (2008).
  • Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. FlexTouch: a prefilled insulin pen with a novel injection mechanism with consistent, high accuracy at low- (1 IU), medium- (40 IU) and high- (80 IU) dose settings. J. Diabetes Sci. Tech. 5(5), 1195–1199 (2011).
  • Garg S, Bailey T, DeLuzio T, Pollom D. Preference for a new prefilled insulin pen compared with the original pen. Curr. Med. Res. Opin. 27(12), 2323–2333 (2011).
  • Bailey T, Thurman J, Niemeyer M, Schmeisl G. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr. Med. Res. Opin. 27(10), 2043–2052 (2011).
  • Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin. Drug Deliv. 8(10), 1259–1269 (2011).
  • Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr. Med. Res. Opin. 28(1), 3–13 (2012).
  • Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual. Life Res. 18(1), 23–32 (2009).
  • Niskanen L, Jensen LE, Rastam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with Type 2 diabetes mellitus. Clin. Ther. 26(4), 531–540 (2004).
  • Pfutzner J, Hellhammer J, Musholt P et al. Evaluation of dexterity in insulin-treated patients with Type 1 and Type 2 diabetes mellitus. J. Diabetes Sci. Technol. 5(1), 158–165 (2011).
  • Kocurek B. Promoting medication adherence in older adults… and the rest of us. Diabetes Spectr. 22(2), 80–84 (2009).
  • Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with Type 2 diabetes: a retrospective database analysis. Clin. Ther. 29, Spec. no.: 1294–1305 (2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.